Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

NCT07470489 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer

Interventions

DRUG: Cemiplimab
DRUG: Zanzalintinib

Sponsor

M.D. Anderson Cancer Center